PathSensors receives expanded license from MIT for CANARY Technology
Summary
This broader license allows PathSensors to move into the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ fast and highly sensitive assays will help to address the shortage of COVID-19 testing capabilities in the United States. The company’s core business is environmental testing in fields such as building protection, mail security, food safety, and agriculture. “Now 8 years later, we are bringing CANARY™ to the healthcare field to provide rapid and highly sensitive detection solutions for a major public health crisis.” About CANARY™ CANARY™ is a biosensor technology that delivers extremely rapid detection of pathogens with high sensitivity and specificity. The company makes the world a safer place by detecting pathogens that can cause sickness or worse while creating high technology jobs in the state of Maryland.